Stay updated with breaking news from Orca T. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In a retrospective analysis, Orca-T improved survival rates vs PTCy in patients with hematologic malignancies receiving myeloablative conditioning.
The use of Orca-T with myeloablative chemotherapy conditioning had comparable safety and efficacy to that of standard allogeneic transplant in younger and older patients with hematologic malignancies, according to data from a phase 1b study.